Numerous strategies have been proposed to specifically inhibit telomerase (human telomerase reverse transcriptase (hTERT)) but to date only a few are clinically relevant in anticancer therapy. Recently, we have shown that long-term treatment with all-trans retinoic acid (ATRA), a compound clinically approved for differentiation therapy of acute promyelocytic leukemia (APL), represses hTERT in differentiation-resistant APL cell lines leading to telomere shortening and death. This signaling requires the co-activation of the retinoic acid receptor a (RARa) and the retinoic X receptor (RXR). In contrast to differentiationtherapy, which is only successful in this subtype of leukemia, the telomerase-targeted pathway could also be of use in non-APL. Here, we demonstrate that repression of hTERT occurs in fresh blasts cells from patients with myeloid leukemias of various subtypes exposed ex vivo to ATRA or synthetic retinoids. These results support the idea that, by hTERT targeting, retinoids can induce telomere shortening and cell death and their integration in therapy protocols for myeloid leukemias refractory to maturation should be considered.
Introduction
Telomerase is a ribonucleoprotein complex responsible for the maintenance of telomeres. Its activity is generally undetectable in normal somatic cells, while it is expressed in approximately 85% of the common cancers. Expression of the catalytic protein component of the telomerase complex, hTERT (human Telomerase Reverse Transcriptase) plays a fundamental role in cellular immortalization. Hematopoietic stem cells express telomerase, [1] [2] [3] but not at a sufficient level to fully maintain telomere length. It is acknowledged that a high level of telomerase activity is detected in acute myeloid leukemia (more than 10-fold compared to normal hematopoietic cells) and during progression of chronic myeloid leukemia (CML). [4] [5] [6] [7] [8] Telomere shortening has also been described associated with progression of myelodysplastic syndrome (MDS) to overt leukemia. 9, 10 As most cancer cells are reliant on telomerase for their survival, it has become a promising target of anticancer therapy. Even though multiple strategies have been described to specifically inhibit telomerase in vitro, 11 most of them have not
been tested yet in clinical trials or are not relevant because of their low efficacy and/or a high toxicity. Among myeloid leukemias, acute promyelocytic leukemia (APL) was found to be particularly sensitive to differentiation therapy using pharmacological doses of all-trans retinoic acid (ATRA), which induce remission of APL patients by stimulating differentiation of leukemic cells. [12] [13] [14] Recently, we identified a new maturation-independent pathway, by which ATRA exerts an antiproliferative activity through hTERT downregulation, leading to telomere shortening and cell death. [15] [16] [17] The significance and extension of this observation to malignancies resistant to retinoid-induced differentiation is currently unknown. Here, we questioned whether hTERT repression by retinoids could occur in blast cells from patients with different subtypes of myeloid leukemias.
Materials and methods

Patients, isolation of white blood cells, cell culture and reagents
Peripheral blood was collected during routine biologic control diagnosis from 21 consenting patients. Mononuclear cells were isolated by Ficoll-Hypaque centrifugation (Eurobio, France). The diagnosis was established according to French-AmericanBritish (FAB) criteria. Patient characteristics and clinical data are summarized in Table 1 . White blood cells, cultured in RPMI 1640 medium (Invitrogen, Cergy Pontoise, France) supplemented with 20% fetal bovine serum (Invitrogen), penicillin (50 IU/ ml), streptomycin (50 mg/ml), L-glutamine (2 mM) were maintained in the dark at 371C in a 5% CO 2 humidified atmosphere (Binder incubator). For in vitro culture treatment, cells were seeded at a density of 1 Â 10 6 cells/ml in medium supplemented with the various agents. ATRA was purchased from Sigma (Saint-Louis MO, USA) and synthetic retinoids with selective specificity for RARa (AM580) and retinoic X receptor (RXR) (CD3640) were provided by CIRD-Galderma (Sophia-Antipolis, Valbonne, France). As previously reported, 17 ATRA, AM580 and CD3640 were used at 1, 0.2 and 0.5 mM, respectively. All cells were maintained in culture as long as the untreated cells demonstrated less than 10% of cell death. Cell death was evaluated on cytocentrifuge slide preparation by morphology after staining with May-Grü nwald-Giemsa.
hTERT mRNA level and telomere length measurements Telomere lengths were determined, after isolation of genomic DNA as described previously, 18 using a non-radioactive chemoluminescent assay developed by Roche Diagnostics (TeloTAGGG telomere length assay). The integrity of the genomic DNA was checked by staining the agarose gel with ethidium bromide.
Statistical analysis
Comparison between groups was analyzed by Student's t-test. Values of Po0.05 were considered to indicate statistical significance. Results are shown as means7s.e. of values obtained in independent experiments.
Results and discussion
According to the FAB classification, three of the 13 acute myeloblastic leukemia (AML) samples studied were classified as M1, three as M2, two as M3, two as M4 and three as M5; the MDS patient was classified as chronic myelomonocytic leukemia (CMML); all the CML patients were in chronic phase ( Table 1 ). The normalized expression of hTERT mRNA level, in cells derived from these patients demonstrated a large interindividual variability (range 10 À3 -10 0 , see Table 1 , right panel) and was undetectable for one patient (Pt no. 13). No obvious correlation between hTERT expressions, clinical features and the type or subtype of myeloid leukemia was observed.
Samples from the above patients were then cultured with or without treatment with 1 mM ATRA, 0.2 mM AM580 (RARaspecific agonist), 0.5 mM CD3640 (RXR-specific agonist) or a combination of both specific agonists. hTERT expression was quantified after 4 days of treatment, a period sufficient to detect telomerase repression when it occurred [15] [16] [17] and in which none of the cultures demonstrated more than 10-20% cell death. To eliminate the variations in hTERT expression observed from patient to patient, and variations that can occur after post ex vivo culture, 5 all relative hTERT levels were presented as percentage of the untreated control collected at the same time. Figure 1a shows that RARa/RXR agonist combination induced a high, homogenous and significant telomerase repression (Po0.01) in 12 of 15 samples derived from the patients. Interestingly, the samples non-responsive to retinoids in terms of telomerase repression were all derived from M1 type AML. Although further studies with larger populations are needed to elucidate the clinical significance of these results, this observation suggests that blasts of this immature subtype might be refractory to hTERT downregulation by retinoids.
The patient samples were divided into two groups, AML samples (excluding those from M1 type for the reasons detailed above) and CML samples. In both groups, retinoid treatment resulted in a significant decrease in hTERT mRNA level (median values of hTERT expression ranging from 72 to 35% of untreated samples in the AML group and from 79 to 38% in the CML group). As no change in cell death was observed during the 4-day treatment, this decrease cannot be related to an alteration in cell viability. Except for the ATRA-treated cells derived from the two AML3 patients (no. 6 and 7) in which repression of . Abbreviations: AML, acute myeloblastic leukemia; CML, chronic myelogenous leukemia; CMML, chronic myelomonocytic leukemia; NA, not available.
Retinoids target hTERT in myeloid leukemias
F Pendino et al hTERT can be associated with differentiation as demonstrated in previous in vitro studies on the myeloid NB4 cell line, 15, 19 no terminal differentiation was observed at 4 days of retinoid treatments in the other patient samples, as expected (the morphology of treated and untreated cells from two patients are shown in Figure 1c ).
RARa/RXR agonist combination treatment showed a high statistical hTERT repression compared to RXR agonist alone (P ¼ 0.002) and RAR agonist (P ¼ 0.03). Although this repression was not highly significantly different from that observed after ATRA treatment (P ¼ 0.07), less variations from patient to patient could be observed (Figure 1b) . Altogether these results show that hTERT repression by retinoids is possible not only in established cell lines as previously shown but also in patient cells. Moreover, the effect is not restricted to maturation responsive cells.
We then wondered whether the observed hTERT downregulation could be enough to decrease sufficiently telomerase activity and lead to telomere shortening and subsequent cell death. However, we were only able to assess the question of the consequence of hTERT repression on telomere length for two samples. This was due to the difficulty to maintain patient cells in culture long enough and in a sufficiently high cell number to perform the telomere length assay. One sample was from an AML1 patient (no. 2), for which no repression was observed and one from an AML5 patient (no. 11), for which hTERT repression occurred. Whereas no change in telomere length was detectable in Patient no. 2 even after 18 days of treatment, a strong telomere shortening (B2 kb) was observed in Patient no. 11 after 11 days of treatment with the RARa/RXR agonist combination (Figure 2) . We have previously demonstrated the existence of distinct thresholds necessary for telomere shortening and cell death, which can vary depending on the targeted cancer cells. 20 It is likely that these thresholds apply also in case of patient cells explaining why despite significant hTERT repression induced by the RARa agonist alone no significant effect on telomere length was observed. Moreover, we cannot exclude that some destabilization of telomere structure may accompany hTERT (19) 81 (9) 63 (4) 52 (3) AML5 Pt 11 96 (10) 34 (9) 72 (0.1) 23 (4) CMML Pt 19 45 (19) 52 (19) 53 (14) 35 (19) CML Pt 12 63 (2) 98 (32) 64 (na) 38 (na) CML Pt 14 55 (36) 61 (15) 60 (15) 67 (na) CML Pt 15 12 (8) nd 98 (49) 18 (4) CML Pt 16 90 (1) 100 (38) 30 (11) 44 (18) CML Pt 17 13 (18) 10 (6) 24 (2) Retinoids target hTERT in myeloid leukemias F Pendino et al repression leading to such a rapid shortening in only 11 days. Nevertheless, this observation is the first demonstration that retinoids can efficiently induce telomere shortening in leukemic blast cells.
The relationship between telomere shortening and induction of cell death was difficult to assess in this study because most of the treated and untreated cells died simultaneously in ex vivo culture within 7-8 days. However, in Patient no. 19, we were able to show that telomerase repression induced by the RARa/ RXR agonist combination was followed by the induction of cell death beginning at day 7 and clearly observed at day 23 ( Figure 3) .
Two recent reports have already tested the therapeutic possibility of antitelomerase drugs for acute myeloid leukemia in freshly isolated leukemia cells from patients. In both cases, the toxic effect appears to derive more from damage of the structure of individual telomeres than from a direct effect at the level of telomerase although additional mechanisms cannot be excluded. 21, 22 Our results demonstrate that (a) retinoids, including ATRA, a clinically approved drug, can target hTERT in cells from patients with myeloid leukemia for which retinoid maturation therapy has not been shown of high efficacy so far and (b) this targeting can result in telomere shortening and subsequent cell death. Although we are aware that our current results are based on a small number of patients, they clearly extend our previous studies reporting a targeting of telomerase expression by ATRA or a combination of RARa and RXR agonists in ATRAmaturation-resistant APL-derived NB4 cells. 15, 17 Together, our results show that antitelomerase activities of retinoids, independent of maturation, are worth to be integrated in therapy protocols for myeloid leukemias refractory to maturation. Retinoids target hTERT in myeloid leukemias F Pendino et al
